Elite Pharma Q1 FY2025 revenue up 109% YoY to $18.8M; operating profit +144%

ELITE PHARMACEUTICALS INC /NV/

2025-Q1 EPS reported $0.00 revenue$18,803,063

Revenue of $18.8M for Q1 ended June 30, 2024, compared to $9.0M in Q1 FY2024.
Operating profit rose to $3.9M from $1.6M YoY, a 144% increase.
Net income attributable to common shareholders was $0.6M.
Growth driven by higher sales of Elite label product line.
Conference call scheduled for August 15, 2024 at 11:30 AM EDT.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.